Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Glucagon-like Peptide 1 Market Forecast Highlighting Growth From $23.88 Billion To $8.6 Billion
The glucagon-like peptide 1 market has witnessed significant growth in recent years. This market is expected to expand from $22.06 billion in 2025 to $23.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This past expansion can be linked to the increasing prevalence of diabetes, rising global obesity rates, broader adoption of injectable peptide therapies, an increasing array of endocrinology treatment options, and the presence of branded glp-1 drugs.
The glucagon-like peptide 1 market is anticipated to show significant growth in the foreseeable future. It is projected to achieve a value of $33.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. This expected increase over the forecast period is driven by factors such as the escalating need for weight management solutions, enhanced investments in the creation of innovative peptide drugs, advancements in oral peptide delivery technologies, a heightened focus on chronic disease management, and the increasing adoption of personalized medicine. Noteworthy trends for the forecast period include the expanding acceptance of GLP-1 therapies for obesity, the continued evolution of oral GLP-1 formulations, a stronger emphasis on long-acting peptide medications, the diversification of combination therapy strategies, and the improvement of patient-centric drug delivery systems.
Download A Free Sample Report For Comprehensive Market Insights:
Glucagon-like Peptide 1 Market Expansion Drivers: What Is Shaping Future Growth?
A growing focus on personalized medicine is anticipated to fuel the expansion of the glucagon-like peptide 1 (GLP-1) market in the future. This approach involves medications that prevent, detect, or address illnesses by leveraging insights into an individual’s genetic makeup or protein profiles. It enables the customization of GLP-1 formulations and dosages to suit specific patient requirements and choices. For instance, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, showed that in 2023, the FDA sanctioned 16 novel personalized treatments for patients with rare diseases, an increase from six in 2022. These recently authorized personalized therapies for 2023 also encompassed seven medications for cancer and three for various other ailments and conditions. Consequently, the heightened focus on personalized medicine is boosting the expansion of the glucagon-like peptide 1 (GLP-1) market.
Glucagon-like Peptide 1 Market Segment Analysis: What Are The Major Market Categories?
The glucagon-like peptide 1 market covered in this report is segmented –
1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems
Glucagon-like Peptide 1 Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Leading companies within the glucagon-like peptide 1 market are concentrating their efforts on advancing technology to enhance therapeutic efficacy, safety, and patient convenience for managing weight and diabetes. Glucagon-like peptide 1 (GLP-1) therapies are injectable, peptide-based medications designed to mimic the body’s natural GLP-1 hormone, thereby regulating appetite, glucose metabolism, and overall body weight. For instance, in March 2024, Novo Nordisk A/S, a pharmaceutical firm based in Denmark, introduced Wegovy, marking it as the first and sole once-weekly GLP-1 therapy specifically for weight management. This particular treatment, developed through the STEP Phase 3a clinical trial program, exhibited a safe and well-tolerated profile, aiming to assist individuals with obesity in both achieving and maintaining weight loss. The availability of a convenient weekly dosing schedule with Wegovy improves patient adherence and addresses the increasing demand for innovative and effective solutions in obesity care.
Glucagon-like Peptide 1 Market Leading Companies Driving Competitive Growth
Major companies operating in the glucagon-like peptide 1 market are Novo Nordisk, Eli Lilly And Company, Pfizer Inc., AstraZeneca Plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Merck And Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson And Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Zealand Pharma A/S, Gan And Lee Pharmaceuticals Co., Ltd.
Access The Complete Glucagon-like Peptide 1 Market Report:
#Glucagon-like Peptide 1 Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the glucagon-like peptide 1 market in 2025. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.